Article Information
- Received November 5, 2020
- Revision received March 8, 2021
- Accepted April 12, 2021
- Published online May 27, 2021.
Author Information
- Lucas Arbabyazd1,*,
- Kelly Shen2,
- Zheng Wang2,
- Martin Hofmann-Apitius3,
- Petra Ritter4,5,6,7,
- Anthony R. McIntosh2,
- Demian Battaglia1,8,# and
- Viktor Jirsa1,#
- 1Institut de Neurosciences des Systèmes, Université Aix-Marseille, Institut ational de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1106, Marseille F-13005, France
- 2Rotman Research Institute, Baycrest Centre, Toronto, Ontario M6A 2E1, Canada
- 3Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin 53754, Germany
- 4Brain Simulation Section, Department of Neurology, Charité University Medicine Berlin and Berlin Institute of Health, Berlin 10117, Germany
- 5Bernstein center for Computational Neuroscience Berlin, Berlin 10117, Germany
- 6Einstein center for Neuroscience Berlin, Berlin 10117, Germany
- 7Einstein center Digital Future, Berlin 10117, Germany
- 8University of Strasbourg Institute for Advanced Studies (USIAS), Strasbourg 67000, France
- Correspondence should be addressed to Lucas Arbabyazd at lucas.arbabyazd{at}gmail.com, Demian Battaglia at demian.battaglia{at}univ-amu.fr, or Viktor Jirsa at viktor.jirsa{at}univ-amu.fr.
Author contributions
Author contributions: L.A., M.H.-A., A.R.M., D.B., and V.J. designed research; L.A., D.B., and V.J. performed research; L.A., P.R., A.R.M., D.B., and V.J. contributed unpublished reagents/analytic tools; L.A., K.S., Z.W., and D.B. analyzed data; L.A., A.R.M., D.B., and V.J. wrote the paper.
Disclosures
The authors declare no competing financial interests.
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense Award Number W81XWH-12–2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. D.B. was supported by the European Union Innovative Training Network “i-CONN” (H2020 ITN 859937); V.J. was supported by the European Union’s Horizon 2020 Framework Program for Research and Innovation under the Specific Grant Agreement No. 785907 (Human Brain Project SGA2) and H2020 Research and Innovation Action grants VirtualBrainCloud; and A.R.M. was supported by the Brightfocus Foundation ADR Grant program, Grant Reference Number A2017286S.
↵* L.A. is first author.
↵# D.B. and V.J. shared last authorship.
Funding
European Commission (EC)
H2020 ITN 859937; Specific Grant Agreement No. 785907 (Human Brain Project SGA2); Innovation Action grants VirtualBrainCloud
Other Version
- You are viewing the most recent version of this article.
- previous version (May 27, 2021).
Online Impact